Novel approaches on prodrug based drug design

Pharmaceutical Chemistry Journal

Volumn 42, Issue 12, 2008, Pages 677-686

  Rasheed, A ^a   Kumar, C K A ^a  

^a Sreevidhyaniketan College of Pharmacy   (India)

Author keywords

[No Author keywords available]

Indexed keywords

(ACYLOXY)ALKYLESTER DERIVATIVE; 2',3' DIDEHYDRO 2',3' DIDEOXYADENOSINE; 2',3' DIDEOXY 2' FLUOROADENOSINE; 2,3 DIDEOXYADENOSINE; [(ALKOXYCARBONYL)OXY]ALKYLESTER DERIVATIVE; ABACAVIR; ACICLOVIR; BETA LACTAM ANTIBIOTIC; BIS[(2 HYDROXYETHYLSULFIDYL) 2 THIOETHYL]; BIS[ACYL 2 THIOETHYL]; CYCLOSPORIN A; FAMCICLOVIR; FLOXURIDINE; GANCICLOVIR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; OLSALAZINE; PENCICLOVIR; PHOSPHORAMIDIC ACID DERIVATIVE; PRODRUG; SALAZOSULFAPYRIDINE; STAVUDINE; SULFAPYRIDINE; THYMIDINE KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; ZIDOVUDINE;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; BLOOD BRAIN BARRIER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TARGETING; ENTERITIS; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE TARGETING; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; STOMACH HEMORRHAGE; STOMACH IRRITATION; STOMACH PERFORATION; STOMACH ULCER; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 67349281451     PISSN: 0091150X     EISSN: 15739031     Source Type: Journal    
DOI: 10.1007/s11094-009-0213-3     Document Type: Review

References (74)

1. SL Timofeevski EF Pnarin OL Vinogradov 1996 Pharm. Res. 13 3 476 480
2. A. Albert, Nature, No. 182, 421-423 (1958).
3. N Bodor P Buchwald 2000 Med. Res. Rev. 20 1 58 101
4. A. Eltahir, S. D. Heys, A. W. Hutcheon, et al., Am. J. Surg., No. 175, 127-132 (1998).
5. G. N. Hortobagyi, Drugs, No. 54, 1-7 (1997).
6. F. L. Moolten, Cancer Res., No. 46, 5276-5281 (1986).
7. A. A. Elshami, A. Saavedra, H. Zhang, et al., Gene Ther., No. 3, 85-92 (1996).
8. S. M. Stribbling, F. Friedlos, J. Martin, et al., Human Gene Ther., No. 11, 258-292 (2000).
9. S. M. Freeman, R. Ramesh, and A. J. Marrogi, Lancet, No. 349, 2-3 (1997).
10. E. C. Mar, J. F. Chiou, Y. C. Cheng, et al., J. Virol., No. 56, 846-851 (1995).
11. T. Tanaka, F. Kanai, S. Okabe, et al., Cancer Res., No. 56, 1341-1345 (1996).
12. M Caruso, Y. Panis, S. Gagandeep, et al., Proc. Natl. Acad. Sci. USA, No. 90, 7024-7028 (1993)
13. C. J. Springer and I. Niculescu-Duvaz, Adv. Drug Deliv. Rev., No. 22, 351-364 (1996).
14. R. Sherwood, R. Melton, S. Alwan, et al., Eur. J. Biochem., No. 148, 447-453 (1985).
15. K. D. Bagshawe, C. J. Springer, F. Searle, et al., Br. J. Cancer, No. 58, 700-703 (1988).
16. R. G. Melton, F. Searle, R. F. Sherwood, et al., Br. J. Cancer, No. 61, 420-424 (1990).
17. D. C. Blakey, B. E. Valcaccia, S. East, et al., Cell. Biophys., No. 22, 1-8 (1993)
18. G. T. Rogers, P. J. Burke, S. K. Shama, et al., Br. J. Cancer, No. 72, 1357-1363 (1995).
19. S. K. Shama, J. A. Boden, C. J. Springer, et al., Cell. Biophys., No. 24, 219-228 (1994).
20. P. F. Torrence, J. Kinjo, S. Khamnei, et al., J. Med. Chem., No. 36, 529-537 (1993).
21. C. K. Chu, V. S. Bhadti, K. J. Doshi, et al., J. Med. Chem., No. 33, 2188-2192 (1990).
22. R. J. Whitley and J. W. Gnann, Engl. J. Med., No. 327, 782-788 (1992).
23. L. D. Lewis, A. S. E. Fowle, and S. B. Bittiner, Br. J. Clin. Pharmacol., No. 21, 459-462 (1986).
24. P. De Miranda and M. R. Blum, J. Antimicrob. Chemother., No. 12 (Suppl. B) 29-37 (1983).
25. M. R. Boyd, T. H. Bacon, and D. Sutton, Antimicrob. Agents Chemother., No. 37, 642-645 (1993).
26. R. A. Vere Hodge, D. Sutton, M. R. Boyd, et al., Antimicrob. Agents Chemother., No. 33, 1765-1773 (1989).
27. F. Peuch, G. Gosselin, I. Lefebvre, et al., Antiviral Res., No. 22, 155-174 (1993).
28. P. Rolan, Clin. Pharmacokinet., No. 29, 333-340 (1995).
29. C. W. Filer, G. D. Allen, and T. A. Brown, Xenobiotica, No. 24, 357-368 (1994).
30. E. B. Roche, Design of Biopharmaceutical Properties through Prodrugs and Analogs. Academy of Pharmaceutical Sciences Symposium, Washington DC (1977).
31. J. K. Sastry, P. N. Nehete, S. Khan, et al., Mol. Pharmacol., No. 41, 441-445 (1992).
32. A. Pompon, I. Lefebvre, J. Imbach, et al., Antiviral Chem. Chemother., No. 5, 91-98 (1994).
33. D. Farquhar, S. Khan, D. N. Srivastva, et al., J. Med. Chem., No. 37, 3902-3909 (1994).
34. R. J. Jones, M. N. Arimilli, M. S. Louie, et al., Abstract Op11; XII International Roundtable Nucleosides, Nucleotides and Their Biological Application, September 15-19, La Jolla, USA (1996).
35. J. Balzarini, S. Aquaro, C. F. Perno, et al., Biochem. Biophys. Res. Commun., No. 219, 337-341 (1996).
36. C. C. Tsai, K. E. Follis, A. Sabo, et al., Science, No. 270, 1197-1199 (1995).
37. K. K. A. Van Rompay J. M. Cherrington, M. L. Marthas, et al., Antimicrob. Agents Chemother., No. 40, 2586-2591 (1996).
38. J. L. Giradet, G. Gosselin, C. Perigaud, et al., Nucleosides Nucleotides, No. 14, 645-647 (1995).
39. S. Benzaria, H. Pelicano, R. Johnson, et al., J. Med. Chem., No. 39, 4958-4965 (1996).
40. I. Lefebvre, C. Perigaud, A. Pompon, et al., J. Med. Chem., No. 38, 3941-3950 (1995).
41. G. Valette, A. Pompon, J. L. Giradet, et al., J. Med. Chem., No. 39, 1981-1990 (1996).
42. C. Meier, Angew. Chem., No. 108, 77-79 (1996).
43. M. Lorey, C. Meier, E. De Clerq, et al., Nucleosides Nucleotides, No. 16, 789-792 (1997).
44. A. Bloch, M. J. Robins, and J. R. McCarthy, J. Med. Chem., No. 10, 908-912 (1967).
45. C. Meier, T. Knispel, V. E. Marquez, et al., J. Med. Chem., No. 42, 1615-1624 (1999).
46. C. McGuigan, M. J. Camarasa, H. Egberink, et al., Int. Antiviral News, No. 5, 19-21 (1997).
47. S. S. Dhaneshwar and S. C. Chadurvedi, East. Pharm., No. 12, 119-122 (1996).
48. N. Gairola, S. S. Dhaneshwar, and S. C. Chadurvedi, Indian J. Pharm. Sci., No. 67, 369-372 (2005).
49. J. C. Burjaud and P. Delsoldato, Curr. Pharma. Des., No. 8, 206 (2002).
50. V. R. Shanbhag and M. J. Crider, J. Pharm. Sci., No. 81, 149 (2002).
51. T. V. Cai, X. Tang, and P. G. Vang, Bio. Org. Med. Chem., No. 11, 4971 (2003).
52. A. A. Khan and J. K. Aroseq, Br. J. Clin. Pharmacol., No. 13, 523 (1982).
53. C. P. Willoughby and E. Anderson, Gut, No. 23, 1081 (1982).
54. C. E. Schacht, Macromol. Chem., No. 191, 529 (1990).
55. J. S. Lee, Y. M. Kim, and Y. I. Jung, Drug. Dev. Ind. Pharm., No. 27, 331 (2001).
56. Y. N. Pang, Z. R. Zhang and Y. Zhang, J. Gastroenterol., No. 15, 913 (2002).
57. E. Roseeuw, G. Marchal, and D. Domurado, Antimicrob. Agents Chemother., No. 47, 34-35 (2003).
58. A. Di Stefano, P. Sozio, and L. S. Cerasa, Molecules, No. 13, 46-68 (2008).
59. N. Bodor and H. H. Farag, J. Med. Chem., No. 26, 528-534 (1983).
60. I. K. Amin, H. Korideck, K. Wang, et al., Molecules, No. 13, 391-404 (2008).
61. F. Leonelli F, A. La Bella, L. M. Migneco, et al., Molecules, No. 13, 360-378 (2008).
62. G. L. Amidon, G. D. Leesman, and R. L. Elliott, J. Pharm. Sci., No. 69, 1363-1368 (1980).
63. P. W. Swaan and J. J. Tukker, J. Pharmacol. Exp. Ther., No. 272, 242-247 (1995).
64. H. K. Han and G. L. Amidon, AAPS Pharms., No. 6, 1-11, (2000).
65. B. Pavan, A. Dalpiaz, N. Ciliberti, et al., Molecules, No. 13, 1035-1065 (2008).
66. L. Perioli, V. Ambrogi, C. Bernardini, et al., Eur. J. Med. Chem., No. 39, 715-727 (2004).
67. R. Kumar, L. Wang, L. I. Wiebe, et al., Arch. Pharm. Pharm. Med. Chem., No. 34, 351-356 (2001).
68. H. S. Oz and L. Jeffrey, Molecules, No. 13, 452-474 (2008).
69. S. B. Hanauer, Aliment. Pharmacol. Ther., Suppl No. 3, 37-40 (2006).
70. S. S. Dhaneshwar, N. Gairola, M. Kandpal, et al., Bioorg. Med. Chem., No. 15, 4903-4909 (2007).
71. M. G. Sandros, C. B. Sarraf, and M. Tabrizian, Molecules, No. 13, 1156-1178 (2008).
72. S. S. Naik, J. F. Liang, Y. J. Park, et al., J. Control. Release. No. 101, 35-45 (2005).
73. M. A. Abeer and P. A. Crooks, Molecules, No. 12, 373-388 (2007).
74. M. R. Hellberg, T. L. Ke, K. Haggard, et al., J. Ocular Pharm. Ther., No. 19, 97-103 (2003).